- In April 2024, Viatris Inc. announced the expansion of its injectable antibiotics portfolio through a strategic collaboration with the Global Antibiotic Research and Development Partnership (GARDP), aiming to improve access to critical treatments for drug-resistant infections in low- and middle-income countries. This initiative reflects Viatris' commitment to global health by increasing the availability of essential generic injectables and addressing the escalating threat of antimicrobial resistance through sustainable and affordable solutions
- In March 2024, Cipla Limited launched a new line of ready-to-use injectable cephalosporins across Southeast Asia and Africa. These formulations, designed for improved stability and ease of administration in resource-limited settings, reinforce Cipla’s focus on addressing unmet needs in infectious disease treatment. The initiative highlights Cipla’s leadership in expanding access to quality injectable generics and enhancing treatment outcomes in high-burden regions
- In March 2024, Hikma Pharmaceuticals plc entered into an agreement with Melinta Therapeutics to commercialize a generic injectable version of meropenem-vaborbactam, a combination antibiotic for treating complicated infections. This move strengthens Hikma’s hospital injectable offerings and reflects the growing importance of combination generics in combating multidrug-resistant pathogens. The partnership underscores industry efforts to broaden access to advanced anti-infective therapies
- In February 2024, Fresenius Kabi announced the launch of its generic line of antiviral injectables, including remdesivir and acyclovir, for hospital use across Europe and Latin America. The products are manufactured in compliance with stringent global standards, highlighting the company’s commitment to delivering high-quality generics to support pandemic preparedness and ongoing treatment of viral infections. This expansion reflects Fresenius Kabi’s strategic focus on biologics and injectables for infectious diseases
- In January 2024, Sandoz revealed its investment in a new sterile injectables manufacturing facility in Slovenia, aimed at increasing the production capacity for critical anti-infective generics. This development supports Sandoz’s goal of strengthening supply chain resilience and meeting growing global demand for injectable antibiotics and antivirals. The facility is expected to play a key role in ensuring a stable supply of essential medicines in times of health crises
